Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;98(4):549-54.
doi: 10.3324/haematol.2012.073601. Epub 2012 Oct 25.

Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation

Affiliations

Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation

Saartje Bloemen et al. Haematologica. 2013 Apr.

Abstract

Anticoagulation by a standard dosage of an inhibitor of thrombin generation presupposes predictable pharmacokinetics and pharmacodynamics of the anticoagulant. We determined the inter-individual variation of the effect on thrombin generation of a fixed concentration of direct and antithrombin-mediated inhibitors of thrombin and factor Xa. Thrombin generation was determined by calibrated automated thrombinography in platelet-poor plasma from 44 apparently healthy subjects which was spiked with fixed concentrations of otamixaban, melagatran, unfractionated heparin, dermatan sulfate and pentasaccharide. The variability of the inhibitory effect of the different anticoagulants within the population was determined using the coefficient of variation, i.e. the standard deviation expressed as a percentage of the mean. The inter-individual coefficients of variation of the endogenous thrombin potential and peak height before inhibition were 18% and 16%, respectively and became 20%-24% and 24%-43% after inhibition. The average inhibition of endogenous thrombin potential and peak height (ETP, peak) brought about by the anticoagulants was respectively: otamixaban (27%, 83%), melagatran (56%, 63%), unfractionated heparin (43%, 58%), dermatan sulfate (68%, 57%) and pentasaccharide (25%, 67%). This study demonstrates that the addition of a fixed concentration of any type of anticoagulant tested causes an inhibition that is highly variable from one individual to another. In this respect there is no difference between direct inhibitors of thrombin and factor Xa and heparin(-like) inhibitors acting on the same factors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Effect of anticoagulants on thrombin generation in normal pooled plasma. Thin black line: no anticoagulant added; line of Xs: 200 nM otamixaban; closed dots: 400 nM melagatran; thin gray line: 0.08 U/mL unfractionated heparin; bold black line: 20 μg/mL dermatan sulfate; open dots: 0.9 μg/mL pentasaccharide.
Figure 2.
Figure 2.
Dose-response curves of ETP and peak height in normal pooled plasma. Open triangles: % inhibition of peak height; closed dots: % inhibition of endogenous thrombin potential (with 5% error bars). (A) otamixaban (B) melagatran, (C) unfractionated heparin, (D) dermatan sulfate, (E) pentasaccharide.

Similar articles

Cited by

References

    1. Bauer KA. New anticoagulants: anti IIa vs anti Xa - is one better? J Thromb Thrombolysis. 2006;21(1):67-72. - PubMed
    1. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med.2009;361(24):2342-52. - PubMed
    1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. - PubMed
    1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. - PubMed
    1. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. - PubMed

MeSH terms